Risk adjusted net present value: What is the current valuation of Pfizer’s PF-07275315?

PF-07275315 is a monoclonal antibody commercialized by Pfizer, with a leading Phase II program in Atopic Dermatitis (Atopic Eczema).

Through the eyes of a cat – biomimicry of feline eyes may revolutionize robotic vision

Researchers developed a feline eye-inspired vision system that uses a vertically elongated pupil and tapetum lucidum mimicry to achieve superior camouflage-breaking and object recognition under

September 25, 2024

School readiness predicts future absenteeism

Children who are not considered “school ready” by their teachers are more than twice as likely to become persistently absent at some point in their

June 27, 2024

Two Pembrolizumab Trials in Head and Neck Cancer Yield Divergent Results

Two first-line trials involving pembrolizumab (Keytruda)-based combinations for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) delivered mixed results. While

March 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.